Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Post-transplant malignancies are one of the leading causes of morbidity, mortality and graft failure in kidney transplant recipients (KTRs). While viral infections and immunosuppressive drugs have historically been considered primary causes, the mechanisms underlying post-transplant cancer occurrence remain incompletely understood, except in certain tumor types. Furthermore, predictive cancer biomarkers have yet to be identified in KTRs
COMETA is a multicenter observational study across four University Italian hospitals. It included pre- and post-kidney transplant patients, with and without cancer. Exclusions: age under 18, cancer within 3 months post-transplant, prior cancer, and HCV/HBV positivity. Approved by Ethics Committees (nr 0029851/I - 2023, Univ. of Campania). Serum miRNAs were extracted, sequenced, and analyzed for differential expression via step-wise bioinformatic and statistical methods.
138 KTRs were enrolled in the study and the analysis of miRNA expression in their sera, and the comparison of data between in-study groups allowed the identification of three miRNA profiles: 1.transplant-related (TR-profile), 2.cancer-related (CR-profile), and 3.cancer-protective (CP-profile) [Fig 1A-B]. In our study, miR-210-3p in CR-profile was firstly found associated with non-melanoma skin cancer (NMSC), whose prevalence in our cohort was relevant. Our results were also successfully validated based on a comparison with TGCA cohort and by matching relevant miRNA with their known biological processes. Using different classifiers, rf classifier based on the TR-miRNAs had a better performance compared to the one based on the GLMnet model (AUC: rf 0.877, AUC GLMnet: 0.807), while the classifier based on the GLMnet model and CR-miRNAs had a better performance compared to the rf classifier (AUC rf: 0.689, AUC GLMnet: 0.781). The classifiers based on the TP-miRNAs showed similar performances (AUC rf: 0.711, AUC GLMnet: 0.701) [Fig. 2].
Our findings firstly support the identification of three key miRNA signatures related to kidney transplant, pro-oncogenic and onco-protective processes in a multicentric KTRs population. To our knowledge, this is a novel finding that opens to the possibility to develop tools for early diagnosis and personalized cancer treatments in KTRs. Moreover, there is no currently data available on the up regulation of miR-210-3p in NSCM, that was a main finding of COMETA study.
